SKIN ELEMENTS LIMITED (SKN)

The suspension of trading in the securities of Skin Elements Limited will be lifted from the commencement of trading on Monday, 4 March 2024 following lodgement of its half year report and Appendix 4D.

The company lodges its Interim financial report and Appendix 4D.

The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Friday, 1 March 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 29 February 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed.

The suspension of trading in the securities of Skin Elements Limited will be lifted from the commencement of trading on Tuesday, 19 October 2021, following the release by SKN of an announcement regarding the completion of a capital raising and confirmation of satisfaction of ASX's conditions for reinstatement.

The company releases the following: Pre-Reinstatement Disclosure, Distribution Schedule, Top 20 Shareholders.

The company releases an application for quotation of securities.

The company releases an updated timetable in relation to the proposed issue of its securiites.

The company releases a prospectus for an offer of up to 1,000 shares at an issue price of $0.08 to raise up to $80.

The company releases a notice of application for quotation of securities.

The company releases an update to its proposed issue of securities. Additional shares were issued from 23,000,000 million to 26,250,000 million.

The company has finalised the placement raising additional funds to a total of $2.1 million in cash to fund its stated business plans including the launch of its new TGA registered SuprCuvr hospital grade disinfectant. The company has issued 26,250,000 ordinary fully paid ordinary shares for $2,100,000 in cash in a private placement to sophisticated investors.

The company lodges the following: Annual Report to shareholders and Appendix 4G Corporate Governance.

The company has today lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 8 September 2021. The update to the timetable is required due to the fact the Company has been finalising matters with ASX in relation to re-quotation.

The company releases an update on the proposed issue of securities. The timetable has been updated.

The company has today lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 25 August 2021.

The company releases an updated notice of proposed issue of securities.

The company lodges its Preliminary Final Report.

The company releases a notice of proposed issue of securities.

The company raised $1.84 million in cash working capital to fund its stated business plans including the launch of is new TGA registered Invisi Shield SuprCuvr hospital grade disinfectant. The company now proposes to issue 23,000,000 ordinary fully paid shares for $1,840,000 in cash (before costs) in a private placement to sophisticated investors under the company's ASX Listing Rule 7.1A placement capacity.

Skin Elements has secured Therapeutic Goods Administration registration of Invisi Shield SuprCuvr as a Hospital Grade Disinfectant. Invisi Shield SuprCuvr is now listed on TGA's Australian Register of Therapeutic Goods "“ the register of therapeutic goods that can be lawfully supplied in Australia ï‚· Invisi Shield SuprCuvr has 99.99999% (7 log reduction1 ) effectiveness against COVID 19 coronavirus. Skin Elements will now move to aggressively pursue and execute commercial-scale sales and distribution opportunities for Invisi Shield SuprCuvr. Invisi Shield SuprCuvr has also been certified as an Input for Organic Production by the National Association for Sustainable Agriculture Australia Organic and Biodynamic Standard.

The company releases an updated notice of proposed issue of securities.

The company has today lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 11 August 2021.

The company as today lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 28 July 2021.

The company releases an updated notice of proposed issue of securities.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The company has today lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 14 July 2021.

The company releases a notice of proposed issue of securities.

The company has today lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 30 June 2021. The update to the timetable is required due to the fact the Company has been finalising matters with ASX in relation to re-quotation.

The company releases an updated notice of its proposed issue of securities.

The company releases an updated notice of proposed issue of securities.

The company has today lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 17 June 2021.

The company continues to be in voluntary suspension due to the fact the company is in continuing negotiations with ASX in relation to re-quotation.

The company has today lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 9 June 2021. The update to the timetable is required due to the fact the Company has been finalising matters with ASX in relation to re-quotation.

The company releases a notice of proposed issue of securities - SKN.

The company releases an updated notice of Proposed issue of securities - SKN.

The company has today lodged an Appendix 3B updating the Entitlement Issue timetable. The update to the timetable is required due to the fact the Company has been finalising matters with ASX in relation to re-quotation.

The company has today lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 24 May 2021. The update to the timetable is required due to the fact the Company has been finalising matters with ASX in relation to re-quotation.

The company releases a notice of Proposed issue of Securities - SKN.

The company has today lodged an Appendix 3B updating the entitlement issue timetable.

The company releases an updated notice of proposed issue of securities.

The company releases a prospectus that contains an offer of up to 1,000 shares at an issue price of $0.10 to raise up to $100.

The company releases a notice of Proposed issue of Securities - SKN.

The company has issued 27,500,000 ordinary fully paid shares to US-based institutional investment group, LDA Capital Limited and LDA Capital LLC, pursuant to the company's $20 million equity funding facility with LDA Capital. The issue of these shares to LDA Capital will allow Skin Elements on requotation to access the first tranche of funding from the $20 million facility with LDA Capital.

The company releases a notice of Proposed issue of Securities - SKN.

The company has lodged an Appendix 3B updating the Entitlement Issue timetable previously announced to the market on 6 April 2021 and updated on 10 May 2021.

The company releases an updated timetable in relation to its entitlement issue.

The company releases an updated otice of Proposed issue of Securities - SKN.

The company has lodged an Appendix 3B updating the Entitlement Issue timetable: Lodge Prospectus with ASIC - 7 May 2021; Ex Date - 12 May 2021; Record Date - 13 May 2021; Prospectus Dispatched to Shareholders - 18 May 2021; Entitlement Offer Opens - 18 May 2021; Last Day to Extend Offer Closing Date - 9 June 2021; Entitlement Offer Closes - 15 June 2021; Announcement of Results - 18 June 2021; Issue date of new securities and lodge an Appendix 2A with ASX - 22 June 2021.

The company releases a notice of Proposed issue of Securities - SKN.

The company lodges its Appendix 4C - quarterly.

The company has lodged an Appendix 3B updating the entitlement issue timetable previously announced.

The company releases an updated notice on the Proposed issue of Securities - SKN.

The company releases a notice of Proposed issue of Securities - SKN.

The company releases a prospectus that contains an offer of up to 1,000 shares at an issue price of $0.10 to raise up to $100.

The company announces a $20 million equity funding facility with LDA Capital Limited and LDA Capital LLC. Skin Elements has entered into a put option agreement with LDA Capital, under which LDA Capital has agreed to provide Skin Elements with up to $20 million in committed equity capital over the next 36 months.

The company releases a notice of Proposed issue of Securities.

The company has finalised arrangements in relation to the underwriting agreement between the company and State Securities. The company will also be undertaking a non-renounceable pro rata entitlement issue at an issue price of $0.08 per share on the basis of 1 new share for every 15 ordinary shares held. Shareholders who subscribe to this will also receive 1 attaching listed option for every 2 new shres issued, excersiable at $0.10 and expiring 3 years after the date of issue. The funds raised will be used to expand the marketing and production of the Invisi-Shield disinfectant range as well as the continued commercialisation of the Soleo Organics natural sun care range and PapayaActiv's therapeutic skincare ange. $10,000,000 pre-factoring finance facility with Custodian Australia remains available for drawdown. The company's shares will remain suspended from trading until such time as the company has responded to any ASX queries.

The Company expects the voluntary suspension to end no later than the commencement of trade on Tuesday 6 April 2021, which it anticipates it will be in a position to make an announcement to the market in respect of the Options Underwriting Agreement and Options Underwriting Shortfall Notice.

The company lodges its Half Yearly Report and Accounts.

ï‚· The Company expects the voluntary suspension to end no later than the commencement of trade on Tuesday 23 March 2021, which it anticipates it will be in a position to make an announcement to the market in respect of the material update to the Options Underwriting Agreement and Options Underwriting Shortfall Notice.

The Company expects the voluntary suspension to end no later than the commencement of trade on Monday 15 March 2021, which it anticipates it will be in a position to make an announcement to the market in respect of a meterial update to the options underwriting agreement and options underwriting shortfall notice.

The Company expects the voluntary suspension to end no later than the commencement of trade on Monday 8 March 2021, which it anticipates it will be in a position to make an announcement to the market in respect of the material update to the Options Underwriting Agreement and Options Underwriting Shortfall Notice, previously announced on 16 April 2020 and 12 January 2021, respectively.

The company lodges its Half Year Accounts.

The voluntary suspension request by the Company is pending the release of an announcement by the Company in regard to a material update to the Options Underwriting Agreement and Options Underwriting Shortfall Notice. The Company expects the voluntary suspension to end no later than the commencement of trade on Monday 1 March 2021, which it anticipates it will be in a position to make an announcement to the market in respect of the aforementioned matter.

The company expects the voluntary suspension of its securities to end no later than the commencement of trade on 22 February 2021, which it anticipates it will be in a position to make an announcement in respect of the options underwriting agreement and options underwriting shortfall notice.

The company expects the voluntary suspension to end no later than the commencement of trade on Monday 15 February 2021, which it anticipates it will be in a position to make an announcement to the market in respect of the material update to the options underwriting agreement and options underwriting shortfall notice.

The company expects the voluntary suspension to end no later than the commencement of trade on 8 February 2021, which it anticipates it will be in a position to make an announcement in respect of the material update to the options underwriting agreement and options underwriting shortfall notice.

The company lodges its Quarterly Activities and Appendix 4C Cashflow Report.

The company releases the results of its meeting.

The company releases its AGM Presentation.

The securities of Skin Elements Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SKN, pending the release of an announcement regarding a material update to the Options Underwriting Agreement and Options Underwriting Shortfall Notice.

The suspension of trading in the securities of Skin Elements Limited will be lifted immediately, following the release by SKN of an announcement regarding an advance of funds in respect of the previously disclosed underwriting agreement.

The underwriter has agreed to advance AU$500,000 to the company by way of unsecured loan. The advance has been received. The agreement in respect of the advance is not amending the UWA.

The securities of Skin Elements Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SKN, pending the release of an announcement regarding an advance of funds in respect of the previously disclosed underwriting agreement.

The suspension of trading in the securities of Skin Elements Limited will be lifted from the commencement of trading on Friday, 16 October 2020, following the release by SKN of an announcement in relation to a company update and a response to an ASX query

The company issues a response to ASX Query Letter.

SKN has continued to manufacture and sell its range of unique all natural skincare technologies. The company has recorded $70,916 in sales through its distributors and its online stores since 30 June 2020. SKN was not able to scale up additional production and use further production funding over the period because of the travel restrictions in place. Four key distributors' outlets are holding significant stocks of the Invisi-Shield Natural sanitiser following the initial impacts of the COVID-19 pandemic. SKN expects to gain sales orders through its distributor channel. Prudential Consultants has agreed to minimum sales commitments of $2.4 million over three years for the exclusive distribution of Invisi ShieldOrganics in New South Wales and Tasmania and also the distribution of Invisi Shield Organics outside of those territories on a non-exclusive basis. Prudential Consultants has taken delivery of samples and training materials and has commenced marketing activities for the Invisi-Shield Natural sanitiser product, however, is yet to place orders with SKN under the distribution agreement. The collaboration agreement with HCT is still on foot. SKN has taken delivery of 174 litres of Path-away and ordered a further 170 litres of Path-away in accordance with the agreement with HCT. Current value of orders and deliveries total $219,901.

SKN is relying on the ASIC Relief and class waiver from ASX listing rule 4.5.1 to extend the lodgment date for its audited Annual Financial Report required to be lodged with ASIC under s319 of the Corporations Act to ASX. SKN is relying upon the ASIC Relief to provide the auditors additional time to obtain sufficient audit evidence given the increased difficulties caused by COVID-19 restrictions including the reduced ability to meet with distributors and production delays from the company's contract manufacturers in Melbourne and Queensland.

The company lodges its Preliminary Final Report.

SKN has made a placement to Mr Garth Alvares, of 2,000,000 ordinary fully paid shares at $0.06 per share with 200,000 free attaching listed options ($0.10 exp 31/12/20) raising $120,000 cash working capital. These shares are issued under the Company's LR 7.1 and LR7.1A capacity. Mr Alvares has recently been appointed as a director of, and become a shareholder of, Prudential Consultants Pty Ltd, a company appointed as a distributor to SKNs Invisi-Shield sanitiser as announced on 7 August 2020. SKN has issued 816,667 ordinary fully paid shares following conversion of $0.03 unlisted options, for $24,500 cash working capital.

The company releases an Appendix 2A.

The company releases a notice of Proposed issue of Securities - SKN.

Skin Elements has entered into a binding distribution agreement with Sydney-based Prudential Consultants for the distribution of the Invisi Shield Organics hand sanitiser. The Agreement represents the first large-scale distribution contract for Invisi Shield Organics and covers major eastern Australian markets at a time of increased demand for hand sanitiser products. Prudential Consultants has agreed to minimum total sales commitments of $2.4 million over three years. Prudential Consultants is a preferred supplier of hand sanitiser to the NSW government and a registered supplier to the Tasmanian Department of Education.

The company lodges its Appendix 4C - quarterly.

The company issues a response to ASX Query Letter.

The company releases a notice of Proposed issue of Securities - SKN.

The Company has completed new securities issues: The issue of 707,702 ordinary fully paid shares following conversion of $0.03 unlisted options; The issue of 250,000 ordinary fully paid shares pursuant to the agreement with Absolut Solutions Pty Ltd for acquisition of the Invisi-Shield sanitiser intellectual property. These shares were issued under the Company's LR7.1 capacity and cleansed under the Company's cleansing prospectus dated 12 June 2020.

The company releases an Appendix 2A.

The company releases an Appendix 2A.

SKN is in confidential and incomplete discussions with its corporate advisors in regard to a potential capital raising on terms consistent with those published. The Company has not executed any binding documentation in relation to the capital raising and there is no guarantee the capital raising will proceed under the terms as detailed in the article or at all.

The company issues a prospectus that contains an offer of up to 1,000 Shares at an issue price of $0.08 to raise up to $80. The prospectus contains an offer of up to 1,000 listed options at an issue price of $0.01 to raise up to $10.

The company releases an Appendix 2A.

The company issues a notice of Proposed issue of Securities - SKN.

The company has completed a number of new securities issues as follows: The issue of 3,451,845 ordinary fully paid shares following conversion of $0.03 unlisted options; The issue of 300,000 ordinary fully paid shares to Custodian Australia Pty Ltd for corporate financial services. These shares are issued under the Company's LR7.1 capacity.

Independent laboratory testing of the SE Formula successfully demonstrates 99.99% effectiveness against Feline Coronavirus, a surrogate of Coronavirus COVID-19. Skin Elements is an established Australian skincare company with track record of USA FDA, TGA and other international regulatory approvals for its Soléo Organics sunscreen and PapayaActivs therapeutic skincare products.

The company issues a response to ASX Query Letter.

The securities of Skin Elements Limited will remain suspended from quotation pursuant to Listing Rule 17.3 pending ASX queries. SKN's securities will remain suspended until further notice.

The securities of Skin Elements Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SKN, pending the release of an announcement regarding laboratory test results.

The suspension of trading in the securities of Skin Elements Limited will be lifted from the commencement of trading on Monday, 23 March 2020, following the release by SKN of an announcement regarding the launch of a new range of products.

As part of its ongoing research and development into natural skincare formulas, Skin Elements has been collaborating with Absolut Solutions Pty Ltd over the past two years on research and development and test marketing in the hand sanitiser products sector. Skin Elements is now proceeding to bring the project to commercialisation as a range of personal care hand sanitisers under the Invisi Shield brand. Invisi Shield is a personal care sanitiser product range that offers personal users broad spectrum antimicrobial control and protection.

The company issues a response to ASX Aware Query.

The company issues a response to ASX Query Letter.

The company releases an Appendix 2A.

The non-renounceable entitlement offer closed the issue on 10 March 2020. The company has notified the underwriter of the entitlement shortfall and it is expected that the new securities will be issued and statements dispatched by 18 March 2020.

The company issues a response to ASX Price Query.

The securities of Skin Elements Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SKN, pending the release of an announcement regarding the Company's response to an ASX query.

The suspension of trading in the securities of Skin Elements Limited will be lifted from the commencement of trading on Monday, 2 December 2019, following the release by SKN of an announcement regarding the appointment of a director and receipt of a response to an ASX Query Letter.

The company releases the Chairman's Address to Shareholders.

The company releases the results of its meeting.

The company issues a response to ASX Query Letter.

The company releases its Corporate Governance Statement.

The securities of Skin Elements Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SKN, pending the release of a response to further queries from the ASX.

The suspension of trading in the securities of Skin Elements Limited will be lifted from the commencement of trading on Tuesday, 26 March 2019, following the release by SKN of an announcement regarding a distribution agreement and response to an ASX price query.

The company issues a response to ASX price query.

The company issues a response to ASX queries regarding its accounts.

The company has executed a proposed major distribution agreement with Henan Huatuo Health Management to deliver at least A$20 million of new sales of Skin Elements all natural skincare products over the years. HHHM intends to distribute Skin Elements products in China via its Huatuo Health Centres. HHHM will undertake a strategic investment in Skin Elements of $2.4 million. HHHM is further incentivised to grow the distribution and product expansion of Skin Elements sales into China over the next three years through the issue by SKN of performance shares.

The securities of Skin Elements Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SKN, pending the release of an announcement.

The suspension of trading in the securities of Skin Elements Limited will be lifted immediately, following the release of a response to an ASX query.

The issue of 500,000 fully paid ordinary shares in SKN to Indian Ocean Capital in lieu of cash consideration for the provision of corporate advisory services resulted in an unintentional breach of Listing Rule 10.11 as shareholder approval was not sought prior to the issue. ASX has permitted these shares to be sold on market and that that proceeds of any profit made on the sale be donated to charity. Indian Ocean has accepted this proposal and will seek to dispose of the shares as soon as possible.

The company retracts, without any admission of liability, the announcement, the research report and the revenue forecasts released on 21 December 2017. SKN advises that the retracted information should be disregarded and that investors should not rely on the retracted information for their investment decisions.

The company issues a response to ASX Query.

The company lodges its Appendix 4C - quarterly.

The company issues a response to ASX Query.

The securities of Skin Elements Limited will be suspended from quotation immediately, in accordance with Listing Rule 17.3, pending a response to an ASX query.

listed entity carried for record purposes only